drugset / Trial / NCT02428712
A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of FORE8394.
Timeline
- Start
- 2015-04
- Primary completion
- 2024-07-12
- Completion
- 2024-07-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Plixorafenib | Small molecule | — | — |
Indications
No indication recorded.